ARQTArcutis Biotherapeutics, Inc.
Price
+53%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $130M in Q2 2026 (quarter ended Jun 30, 2026), up 59% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $15M (12% of revenue). For the full year FY2025, revenue was $376M (+91% year on year) and net income −$16M. Its largest product in Q2 2026 was ZORYVE Foam at $67M, 52% of the disclosed total, well ahead of ZORYVE Cream0.3 at 27%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.Earnings release · Form 8-K
- Jul 16, 2026On July 15, 2026, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board.Director or officer change · Form 8-K
- Jun 9, 2026As part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualified members of the Company’s Board of Directors (the “Board”), which includes compensating eligible non-employee directors appropriately for their services, the Compensation …Shareholder vote results · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $129.9MThe company’s own SEC segment disclosure.
- ZORYVE Foam$67.4M52%
- ZORYVE Cream0.3$35.3M27%
- ZORYVE Cream0.15$24.2M19%
- ZORYVE Cream0.05$2.9M2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.